MEP14408A - 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds - Google Patents

4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Info

Publication number
MEP14408A
MEP14408A MEP-144/08A MEP14408A MEP14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A
Authority
ME
Montenegro
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
halogenated
Prior art date
Application number
MEP-144/08A
Other languages
Bosnian (bs)
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Guenter Kaufmann
Hans-Udo Schweikert
Gerd Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MEP14408A publication Critical patent/MEP14408A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pronalazsak se odnosi na 17-metilen steroide, postupak za njihovu proizvodnju i farmaceutske sastave koji sadrže ova jedinjenja. Jedinjenja u skladu sa pronalasakom imaju profil dejstva hibridnog tipa u smislu da se ponašaju kao inhibitori 5α-reduktaze i simultano kao gestageni. Oni su zbog toga pogodni za liječenje bolesti koje su rezultat povišenih nivoa androgena u određenim organima i tkivima kod muškaraca i žena. Zajedno sa drugim hormonalnim supstancama, kao što su estrogen, testosteron, ili jaki androgen, jedinjenja u skladu sa pronalaskom su pogodna kao kontraceptivna sredstva za žene i muškarce.The invention relates to 17-methylene steroids, a process for their production and pharmaceutical compositions containing these compounds. The compounds according to the invention have an action profile of the hybrid type in the sense that they act as 5α-reductase inhibitors and simultaneously as progestogens. They are therefore suitable for the treatment of diseases that result from elevated androgen levels in certain organs and tissues in men and women. Together with other hormonal substances, such as estrogen, testosterone, or strong androgen, the compounds according to the invention are suitable as contraceptives for women and men.

MEP-144/08A 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds MEP14408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (en) 2000-09-04 2000-09-04 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/009943 WO2002019971A1 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
MEP14408A true MEP14408A (en) 2010-06-10

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-144/08A MEP14408A (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Country Status (29)

Country Link
EP (1) EP1423407B1 (en)
JP (1) JP2004513084A (en)
KR (1) KR100530816B1 (en)
CN (1) CN1262560C (en)
AT (1) ATE319733T1 (en)
AU (2) AU1047002A (en)
BG (1) BG107594A (en)
BR (1) BR0113618A (en)
CA (1) CA2421302C (en)
DE (2) DE10043846A1 (en)
DK (1) DK1423407T3 (en)
EA (1) EA006387B1 (en)
EE (1) EE05186B1 (en)
ES (1) ES2260294T3 (en)
HK (1) HK1060135A1 (en)
HR (1) HRP20030256A2 (en)
HU (1) HUP0300936A3 (en)
IL (2) IL154666A0 (en)
ME (1) MEP14408A (en)
MX (1) MXPA03001912A (en)
NO (1) NO325012B1 (en)
NZ (1) NZ524485A (en)
PL (1) PL360669A1 (en)
PT (1) PT1423407E (en)
RS (1) RS50305B (en)
SK (1) SK286757B6 (en)
UA (1) UA74592C2 (en)
WO (1) WO2002019971A1 (en)
ZA (1) ZA200301715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (en) 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
DE202007019049U1 (en) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Use of a gestagen in combination with an estrogen for the prophylaxis of lactose intolerance in oral contraception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP1409512A1 (en) * 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
CA2421302C (en) 2007-08-14
PL360669A1 (en) 2004-09-20
EP1423407A1 (en) 2004-06-02
WO2002019971A9 (en) 2002-08-08
HUP0300936A2 (en) 2003-11-28
ZA200301715B (en) 2004-08-13
NO325012B1 (en) 2008-01-14
ES2260294T3 (en) 2006-11-01
SK286757B6 (en) 2009-05-07
EA200300322A1 (en) 2003-10-30
EP1423407B1 (en) 2006-03-08
PT1423407E (en) 2006-07-31
HRP20030256A2 (en) 2005-10-31
IL154666A0 (en) 2003-09-17
EE05186B1 (en) 2009-06-15
NO20030989L (en) 2003-05-02
UA74592C2 (en) 2006-01-16
IL154666A (en) 2008-12-29
AU2002210470B2 (en) 2006-07-20
HUP0300936A3 (en) 2010-01-28
JP2004513084A (en) 2004-04-30
WO2002019971A1 (en) 2002-03-14
RS50305B (en) 2009-09-08
BR0113618A (en) 2003-07-15
KR20030028836A (en) 2003-04-10
KR100530816B1 (en) 2005-11-25
DE50109175D1 (en) 2006-05-04
NO20030989D0 (en) 2003-03-03
SK2442003A3 (en) 2003-08-05
YU16403A (en) 2006-05-25
DE10043846A1 (en) 2002-04-04
EE200300087A (en) 2005-02-15
ATE319733T1 (en) 2006-03-15
AU1047002A (en) 2002-03-22
NZ524485A (en) 2005-11-25
BG107594A (en) 2003-09-30
MXPA03001912A (en) 2004-07-08
EA006387B1 (en) 2005-12-29
CA2421302A1 (en) 2003-03-03
CN1452628A (en) 2003-10-29
CN1262560C (en) 2006-07-05
DK1423407T3 (en) 2006-07-03
HK1060135A1 (en) 2004-07-30

Similar Documents

Publication Publication Date Title
NO20091190L (en) Methods and compositions for the treatment of cancer
BR112012009306A2 (en) method for myelin regeneration in a patient
NO20020651L (en) Birch bark treatment and isolation of natural products from birch bark
FR2814074B1 (en) NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT
AR057060A1 (en) TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL
MX2022013429A (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide.
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
MX2019001327A (en) Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride.
DE60330695D1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING 15-HYDROXYTESTOSTERONE AND ITS DERIVATIVES
NO20053626L (en) A composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen for use in the treatment of endomeriosis
BR0008437A (en) Steroid sulfatase inhibitors and methods for their manufacture and use
HUP9903747A2 (en) New process for the preparation of mometasone furoate
MEP14408A (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
TW200612962A (en) Estriol and estetrol prodrugs
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
NO20054636L (en) Process for the preparation of steroidal carbothioic acid derivatives and intermediates
ATE470669T1 (en) D-(17ALPHA)-13-ETHYL-17HYDROXY-18,19-DINORPREGN 4-ENE-20-YNE-3-ONE IN THE FORM OF THE PURE 3E AND 3Z OXIMES AND THE PROCESS FOR PRODUCING THE MIXTURE OF THE ISOMERS AS WELL AS THE PURE ISOMERS
DK1910398T3 (en) 17-alpha-substituted derivatives of estradiol with wound healing effect
AR003967A1 (en) (22R) -N- (1,1,1-TRIFLUORO-2-PHENYLPROP-2-IL) -3-OXO-4-AZA-5ALFA- ANDROST-1-ENO-17BETA-CARBOXAMIDE EPIMERES, A PROCESS FOR YOUR PREPARATION AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTAND THEM.
Ben-juan et al. Hydrogen peroxide induced apoptosis in SV-40 transformed human salivary gland acinar cells
DE502004004976D1 (en) USE OF AN OXYTOCIN AND TESTOSTERONE OR ESTRADIOL-CONTAINING MIXTURE FOR TREATING DISORDERS OF PSYCHOSOCIAL EXPERIENCE AND BEHAVIOR
AR107833A1 (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND USES OF THE SAME